Corcept Therapeutics (CORT) Other Accumulated Expenses (2010 - 2025)

Corcept Therapeutics (CORT) has 14 years of Other Accumulated Expenses data on file, last reported at $34.0 million in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses changed 0.25% year-over-year to $34.0 million; the trailing twelve-month figure through Dec 2025 stood at $34.0 million (changed 0.25% YoY), and the FY2025 full-year result was $34.0 million, changed 0.25% from the prior year.
• Other Accumulated Expenses climbed to $34.0 million in Q4 2025, from $28.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $34.0 million in Q4 2025 to a low of $12.4 million in Q4 2021.
• A 5-year average of $23.1 million and a median of $21.7 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 58.78% in 2024 and climbed 0.25% in 2025, its largest moves.
• Tracing CORT's Other Accumulated Expenses over 5 years: stood at $12.4 million in 2021, then increased by 17.13% to $14.6 million in 2022, then soared by 46.37% to $21.3 million in 2023, then jumped by 58.78% to $33.9 million in 2024, then increased by 0.25% to $34.0 million in 2025.
• Business Quant data shows CORT's Other Accumulated Expenses at $34.0 million in Q4 2025, $28.3 million in Q3 2025, and $29.0 million in Q2 2025.